MedTrace Logo

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

NCT02788773 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-05-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out the effects of giving durvalumab alone or in combination with tremelimumab on this type of cancer. In addition, this study will look at the side effects of durvalumab when given alone or in combination with tremelimumab.

Conditions

Interventions

DRUG

Durvalumab

DRUG

Tremelimumab

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Sebastien Hotte · Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON Canada

  • Eric W Winquist · London Regional Cancer Program, London ON Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-15
Primary Completion
2021-11-22
Completion
2025-05-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02788773 on ClinicalTrials.gov